Welcome to our dedicated page for Pulmatrix news (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix stock.
Pulmatrix, Inc. (PULM) generates news primarily as a clinical-stage biopharmaceutical company focused on inhaled therapeutics built on its patented iSPERSE™ dry powder technology. Company announcements frequently highlight developments in its pipeline of inhaled product candidates for central nervous system and respiratory diseases, including acute migraine, COPD and allergic bronchopulmonary aspergillosis.
News updates often cover clinical milestones for PUR3100, an orally inhaled dihydroergotamine (DHE) candidate for acute migraine, such as publication of Phase 1 results in a peer-reviewed journal and regulatory progress following FDA acceptance of an Investigational New Drug application and a “study may proceed” letter for a Phase 2 study. Pulmatrix also reports on PUR1800, a Narrow Spectrum Kinase Inhibitor for acute exacerbations in chronic obstructive pulmonary disease, including Phase 1b safety and tolerability data, and on PUR1900, its inhaled itraconazole formulation being advanced with partner Cipla outside the United States.
Investors following PULM news will also see regular corporate and strategic updates. These include quarterly and annual financial results, descriptions of cost-saving measures and Pulmatrix’s transition toward a more virtual operating model. The company has issued multiple releases about its proposed merger with Cullgen Inc., detailing stockholder approvals, regulatory steps such as the effectiveness of a registration statement on Form S-4, and conditions to closing, including Nasdaq and China Securities Regulatory Commission approvals. Pulmatrix has also reported entering into a mutual waiver agreement with Cullgen to allow both parties to explore alternative transactions while continuing to pursue the merger.
Additional news items describe licensing and collaboration activity, such as the cross-license agreement and facility transfer with MannKind Corporation involving iSPERSE™ and MannKind’s Cricket® inhalation device. For readers tracking PULM, this news page provides a centralized view of clinical data releases, regulatory filings referenced in press releases, strategic transactions and financial updates that shape the company’s evolution and its inhaled therapeutic programs.
Pulmatrix, Inc. (NASDAQ: PULM) announced successful results from a Phase 1 trial of PUR3100, an inhaled dihydroergotamine formulation aimed at treating acute migraines. Conducted on 26 healthy subjects, the trial showed that PUR3100 was well-tolerated, with fewer gastrointestinal side effects compared to intravenous DHE. It achieved a five-minute Tmax and Cmax within the therapeutic range across all doses. The company plans to discuss findings with the FDA and prepare for a Phase 2 study, signaling progress in addressing a critical healthcare need for migraine treatment.
Pulmatrix, Inc. (PULM) reported Q3 2022 revenues of $1.9 million, a $0.8 million increase year-over-year. The rise was mainly due to revenue from the PUR1900 program. However, total revenues are down from $4.713 million in the nine months ended September 2021 to $4.363 million in the same period of 2022. R&D expenses rose $1.3 million to $5.3 million, largely driven by PUR1900 clinical costs. The company has $40.7 million in cash, expected to cover operations into Q2 2024, and is advancing both PUR3100 and PUR1900 towards pivotal trial stages.
Pulmatrix, Inc. (NASDAQ: PULM) announced the completion of dosing in a Phase 1 trial for PUR3100, an orally inhaled formulation of dihydroergotamine (DHE) for acute migraine treatment. The trial enrolled 26 healthy volunteers, assessing safety and pharmacokinetics across three dose groups. Phase 1 data is expected in Q4 2022. The company highlights a significant need for new options as 75% of migraine sufferers do not find relief with current medications. CEO Ted Raad expressed optimism for PUR3100's potential to be a best-in-class product.
Pulmatrix, Inc. (NASDAQ: PULM) reported financial results for Q2 2022, revealing a revenue decrease to $1.3 million from $2.2 million in Q2 2021. The net loss widened to $4.6 million compared to $3.9 million in the prior year. Cash and cash equivalents stand at $42.9 million, expected to sustain operations until Q2 2024. The company is advancing its therapies with PULM on track for Phase 2b study of Pulmazole in Q1 2023 and PUR3100 Phase 1 study underway, with data expected by Q4 2022.
Pulmatrix, Inc. (NASDAQ: PULM) announced the dosing of the first five subjects in a Phase 1 trial for PUR3100, an inhaled formulation of dihydroergotamine (DHE) aimed at treating acute migraines. The double-blind trial will assess the safety and pharmacokinetics of three doses of PUR3100 against IV DHE. This innovative approach could offer a more convenient alternative to current treatments. Results are expected in Q4 2022, which will inform future efficacy studies. The company aims for PUR3100 to be a best-in-class product for migraine therapy.
Pulmatrix, Inc. (NASDAQ: PULM) reported Q1 2022 results with $1.2 million in revenue, a decline from $1.4 million in Q1 2021. The company ended the quarter with $47.5 million in cash, extending its cash runway into Q2 2024.
Research and development costs increased to $4.1 million, while general administrative expenses rose to $2.0 million. The net loss for Q1 2022 was $4.973 million with a loss per share of $1.51. The Pulmazole Phase 2b study is slated to begin in Q1 2023, with top-line data expected in Q2 2024.
Pulmatrix, Inc. (NASDAQ: PULM) reported its 2021 financial results, revealing a revenue drop to $5.2 million from $12.6 million in 2020, attributed to lower collaboration revenues. Research and development expenses slightly decreased, while general and administrative costs also fell. The company raised $46.75 million in 2021 and has enough cash to fund operations through Q1 2024. Significant upcoming trials include a Phase 2b study for Pulmazole and a Phase 1 study for PUR3100. Pulmatrix also regained compliance for Nasdaq listing and appointed Dr. Margaret Wasilewski as Chief Medical Officer.
Pulmatrix, Inc. (NASDAQ: PULM) announced positive top-line results from its Phase 1b clinical trial of PUR1800, aimed at treating Acute Exacerbations in Chronic Obstructive Pulmonary Disease (AECOPD). Conducted in Manchester, UK, the study evaluated safety, tolerability, and pharmacokinetics (PK) over 14 days with 18 participants. Results showed that PUR1800 was well-tolerated, demonstrating low and consistent systemic exposure. Executives expressed confidence in advancing PUR1800 to Phase 2 studies, supported by favorable chronic toxicology results.
Pulmatrix, Inc. (NASDAQ: PULM) announced it has regained compliance with Nasdaq's minimum bid price requirement as of March 14, 2022. The company was initially notified on August 17, 2021, for failing to maintain a minimum bid price of $1.00 for 30 consecutive business days. Following its compliance, the matter has now been resolved. Pulmatrix specializes in developing inhaled therapies for serious pulmonary and non-pulmonary diseases using its patented iSPERSE™ technology, targeting conditions such as ABPA and COPD.
Pulmatrix, Inc. (NASDAQ: PULM) announced the appointment of Dr. Margaret Wasilewski as Chief Medical Officer, effective March 1, 2022. Dr. Wasilewski has over 25 years of pharmaceutical experience and will enhance Pulmatrix's clinical strategy and pipeline development. CEO Ted Raad expressed confidence in her leadership abilities, highlighting the potential for significant advancements in Pulmatrix's innovative inhaled therapies targeting serious pulmonary and neurological diseases. The company aims to leverage Dr. Wasilewski's expertise to drive clinical trial milestones and explore new opportunities for unmet medical needs.